Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Related GALE
Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients
Galena Biopharma Launches Zuplenz Oral Soluble Film

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

Sep 2015Raymond JamesInitiates Coverage onOutperform
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (GALE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters